Blogs

seven-months-to-brexit-does-the-biopharma-industry-have-the-tools-to-be-ready

Seven months to Brexit, does the biopharma industry have the tools to be ready?

Everything you need to know about the latest Brexit White Paper By Joanna Fernandes, Analyst Email: jfernandes@partners4access.com As the countdown to Brexit draws near, a flurry of activities has emerged from the UK government, the EU and the pharma/biotech industry. But central to the conversation is the recent white paper released by the UK government […]

Read More

slow-brexit-proceedings-frustrates-biotech-industry

Slow Brexit proceedings frustrates biotech industry

By Aparna Krishnan, Corporate Affairs Lead As the UK Prime Minister’s office is preparing for the cabinet meeting at Chequers this Friday, British businesses including the biotech industry are none the wiser on what lays ahead after March 29, 2019 when the UK exits the European Union. The current discussion is focussed on the Brexit […]

Read More

faster-route-to-access-in-scotland-for-rare-disease-patients-requiring-ultra-orphan-drugs

Faster route to access in Scotland for rare disease patients requiring ultra-orphan drugs

By Alison Kneen, Vice President International Operations Fantastic news for Scottish patients who suffer from very rare diseases. As of October 1, 2018, patients will receive faster access to new treatments as a result of changes being made to the Scottish Medicine Consortium (SMC), the health technology assessment (HTA) body pathway which is used to evaluate […]

Read More

cancer-diagnosis-a-step-forward-for-england

Cancer diagnosis – a step forward for England

New rapid diagnostic and assessment centres are being piloted in ten areas across England in a focused approach to identify cancer early.  These new centres are part of the NHS plan to meet the new faster diagnosis standard, where patients with suspected cancer should receive a diagnosis or given the all clear within 28-days. The […]

Read More

prime-two-year-assessment-was-it-good-for-biopharma

PRIME – two-year assessment – was it good for biopharma?

The PRIority Medicines Scheme (PRIME) of the European Medicines Agency (EMA) was started two years ago to support and optimise medicine development. The scheme provides early and enhanced scientific and regulatory support to medicines that have the potential to significantly address patients’ unmet medical needs. The EMA has published their two-year review and not surprisingly more than […]

Read More

irish-patients-continue-to-be-denied-vital-new-drugs

Irish patients continue to be denied vital new drugs

Todays’ article in the Irish Times[1] highlights again that patients in Ireland continue to be denied nine drugs which are already approved for use by the National Centre of Pharmacoeconomics (NCPE). They have been waiting on average for 2 years for the Health Service Executive (HSE) to approve them for reimbursement. The drugs concerned range […]

Read More

cancer-treatments-a-brief-history

Cancer treatments: A brief history

February 4 was World Cancer Day and here at Partners4Access, we are having a look back at how cancer treatments have evolved through the years and where they are likely to go in the future. First came surgery In the 18th century, surgery was hailed as the first effective cancer treatment. The discovery of anesthesia […]

Read More

though-there-is-some-way-to-go-nice-is-moving-in-the-right-direction-on-htas

Though there is some way to go, NICE is moving in the right direction on HTAs

  From 1 March 2000 to 31 December 2017, NICE (National Institute for Health and Care Excellence) published over 800 healthcare technology recommendations. In total, 81% of those decisions were recommended, optimized or recommended for use in the Cancer Drugs Fund (CDF). Why then is NICE considered such a tough cookie when it comes to […]

Read More

orphan-drug-pricing-is-eurordis-call-to-reduce-prices-by-3-5-times-the-answer-to-unequitable-access

Orphan Drug Pricing: Is Eurordis call to reduce prices by 3-5 times the answer to unequitable access?

Partners4Access comments on the new Eurordis Position Paper Earlier this month Eurordis published its position paper on orphan drug access. Whilst the report is commendable in pushing to drive equitable access for patients; their call to reduce orphan drug prices by 3 to 5 times by 2025 is no guarantee of full patient access. Affordability […]

Read More

european-pmaa-consolidation-a-paradigm-shift-and-implications-for-pharma

European P&MA Consolidation: A Paradigm Shift and Implications for Pharma

Earlier this month, Italy’s Health Minister, Beatrice Lorenzin, announced that two additional countries- Slovenia and Croatia- had signed up to the Valletta Declaration. Of the 28 EU member states, over a third (10 countries*) are now part of the initiative which aims to strengthen their bargaining power over pharmaceutical companies through collective price negotiations and […]

Read More

All Rights Reserved ©   Privacy   Partners 4 Access 2018